Brought to you by 
Drug delivery start-up Lyndra brings in $23mm through Series A round
18 Apr 2017
Executive Summary
Lyndra Inc. (develops sustained-release oral dosage forms) closed a $23mm Series A round led by Polaris Partners. Quark Venture, GF Securities, Yonghua Capital, Healthlink Capital, Partners Healthcare, and Suffolk Equity also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Drug delivery start-up Lyndra brings in $23mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice